A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted Immunochemotherapy

Treatment and Treatment Duration Neoadjuvant chemotherapy will begin on Day 1 of Cycle 1 and will be administered every 2 weeks for a total of 4 cycles. After surgery, XELOX, which is currently used as standard adjuvant chemotherapy, will be administered for 6-8 cycles at the physician's discretion. Study Duration The study duration is expected to be approximately 3 years from the date of IRB approval. (The study duration may be subject to change depending on the enrollment rate.) Number of Subjects The target enrollment for this study is 20 subjects. Investigational Products, Dose, and Rou

Trial Details

NCT ID
NCT07911280
Phase
PHASE2
Sponsor
Samsung Medical Center
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Trastuzumab + Durvalumab + FLOT
Locations (sample)
  • Seoul, Gang-Nam, South Korea|37.566,126.9784

Key Eligibility Criteria

  • 1\. The subject must provide written informed consent prior to any study-specific procedures after receiving adequate information regarding the study.
  • 2\. The subject must be ≥19 years of age. 3. Body weight \>30 kg. 4. Histologically documented adenocarcinoma of the stomach or gastroesophageal ju…
  • 5\. Confirmed HER2-positive disease, defined as HER2 IHC 3+ or HER2 IHC 2+/SISH-positive.
  • 6\. Locally advanced, resectable gastric or gastroesophageal junction cancer as determined by the investigator (e.g., cT2 or higher and/or node-pos…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →